New Treatment for Ischemic Hearing Loss with PRP-hydrogel

2021 Fiscal Year Final Research Report

• Project/Area Number: 20K23004
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0906:Surgery related to the biological and sensory functions and related fields
• Research Institution: Ehime University
• Principal Investigator: Takagi Taro 愛媛大学, 医学部附属病院, 助教 (20601024)
• Project Period (FY): 2020-09-11 – 2022-03-31
• Keywords: 突発性難聴 / 虚血性内耳障害 / 成長因子 / CGF / PRP

Outline of Final Research Achievements

Concentrated growth factors (CGF) are attracting attention as the next generation of PRP. CGF is more easily isolated and extracted than PRP, and can be purified completely from autologous blood without the use of platelet aggregation attractants, thrombin, calcium chloride, or other substances required in the PRP purification process. CGF has the advantage of being purified as a gel-like substance, which allows for sustained release of growth factors. Therefore, it does not need to be impregnated in a gelatin hydrogel like PRP.
It is now possible to purify CGF using gerbils. We plan to administer CGF to a gerbil model of transient inner ear ischemia and test its efficacy.

Free Research Field

神経耳科学

Academic Significance and Societal Importance of the Research Achievements

突発性難聴の治療法は、現在も確立されておらず、治療後も十分に聴力が回復しない場合が多い。突発性難聴の原因として、内耳の循環不全による虚血性障害が挙げられる。われわれはスナネズミ虚血性内耳障害モデルを用いて、突発性難聴に対する新たな治療法の開発に取り組んできた。
これまでの研究で、われわれは虚血性内耳障害に対し、成長因子が障害抑制作用を有することを示してきた。成長因子を豊富に含有するCGFは、突発性難聴の治療法の一つになりうる可能性がある。